Novo Nordisk A/S (NYSE:NVO)
| 107.83 Delayed Data As of 3:59pm ET |  +0.08 / +0.07%Today’s Change | 78.71 Today|||52-Week Range 122.16 | -3.72% Year-to-Date |
Latest NVO News | Press Releases
| Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo May 20 / Zacks.com - Paid Partner Content | Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod May 16 / Zacks.com - Paid Partner Content |
| Is Perrigo a Buy After Reporting Q1 Earnings? May 20 / StockNews.com - Paid Partner Content | How Novo Nordisk Will Protect Insulin Sales May 12 / MotleyFool.com - Paid Partner Content |
| 4 Large Drug Stocks to Watch as the Industry Recovers May 19 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 107.75 |
| Today’s open | 107.95 |
| Day’s range | 107.29 - 108.43 |
| Volume | 823,702 |
| Average volume (3 months) | 1,505,739 |
| Market cap | $187.3B |
Data as of 3:59pm ET, 05/23/2022
Growth & Valuation
| Earnings growth (last year) | +19.70% |
| Earnings growth (this year) | +7.43% |
| Earnings growth (next 5 years) | +14.39% |
| Revenue growth (last year) | +15.27% |
| P/E ratio | 34.9 |
| Price/Sales | 11.53 |
| Price/Book | 22.69 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NVSNovartis | +1.30 | +1.45% |
| AZNAstraZeneca | +0.20 | +0.30% |
| BMYBristol-Myers Squibb | +0.50 | +0.66% |
| MRKMerck | +0.30 | +0.32% |
Data as of 5:52pm ET, 05/23/2022
Financials
| Next reporting date | August 4, 2022 |
| EPS forecast (this quarter) | $0.83 |
| Annual revenue (last year) | $22.4B |
| Annual profit (last year) | $7.6B |
| Net profit margin | 33.92% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Bagsværd, Capital Region |
Forecasts
